Any current/future new fundraising through debt or equity?

Current CAPEX already incurred is around Rs.18-19 crores (Rs.7.5 crores building, Rs.11.5 crores machinery). No major CAPEX planned except adding one line in API for new GMP. Company has enough reserves for CAPEX; may borrow 1-2 crores from bank if needed but is largely self-reliant. Cash and cash equivalents exceed outside borrowings by at least Rs.1 crore, indicating no immediate debt raising. No mention of any current or near-term equity fundraising in the call. Focus is on internal accruals and maintaining low-cost finance (CFO’s bandwidth includes getting lowest interest rate and maximizi

Future growth expectations in sales/revenue/volumes?

Beta Drugs Limited targets a consistent revenue growth of around 30% annually for the next 3-4 years. Growth will be driven by strong organic growth in domestic markets, new product launches, and export market expansion. Exports contribution expected to rise from current low levels to around 30%-35% in the next 3-4 years, focusing on regulated developing markets like Latin America, CIS, and Southeast Asia. CRAMS (contract manufacturing) revenue share is expected to reduce in proportion but will still grow in absolute terms. Domestic market growth expected through penetration in tier-2 and tier

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth guidance of 30% annually for the next 3-4 years (Page 6). EBITDA margin expected to improve by 100 basis points in FY22-23 from 24% to 24.5%, targeting 26-27% margins in 3-4 years (Page 6). Net profit increased by 112% in FY22 already, signaling strong earnings momentum (Page 2). EBITDA margin expansion driven by higher sales of own brands, exports, and cost realizations (Page 2). Further margin improvement expected from increased penetration in international markets which have higher price realization (Page 6). Continued focus on new product launches, market penetration especia

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected orderbook or pending orders in exact figures. Rahul Batra emphasizes a large and aggressive product development pipeline with 35 new molecules planned by 2025. The company is focused on launching 8-12 molecules by 2023-24, indicating strong future order potential. There is an ongoing effort to build international client relationships, especially in CIS countries and exports, suggesting growing order inflow over the next few years. Capacity utilization shows levers: 60%-70% available for oral facility and 40%-50% for injectable

Beta Drugs LtdQ4 FY22Pharmaceuticals & Biotechnology

Beta Drugs Ltd Q4 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,118P/E: 51.5Market Cap: ₹2.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Beta Drugs Limited targets a consistent revenue growth of around 30% annually for the next 3-4 years.
Growth will be driven by strong organic growth in domestic markets, new product launches, and export market expansion.
Exports contribution expected to rise from current low levels to around 30%-35% in the next 3-4 years, focusing on regulated developing markets like Latin America, CIS, and Southeast Asia.
CRAMS (contract manufacturing) revenue share is expected to reduce in proportion but will still grow in absolute terms.
Domestic market growth expected through penetration in tier-2 and tier-3 cities and expansion in hospital tie-ups.
Revenue generation potential from current capacity is Rs.300-350 crores with leverage of 40%-70% in existing facilities.
EBITDA margins expected to improve, possibly reaching 26%-27% in 3-4 years aided by export market growth.
New product pipeline includes 35 molecules planned for launch by 2025, maintaining continuous product flow.

Margin guidance

Category 2

Revenue growth guidance of 30% annually for the next 3-4 years (Page 6).
EBITDA margin expected to improve by 100 basis points in FY22-23 from 24% to 24.5%, targeting 26-27% margins in 3-4 years (Page 6).
Net profit increased by 112% in FY22 already, signaling strong earnings momentum (Page 2).
EBITDA margin expansion driven by higher sales of own brands, exports, and cost realizations (Page 2).
Further margin improvement expected from increased penetration in international markets which have higher price realization (Page 6).
Continued focus on new product launches, market penetration especially in domestic and regulated markets supports sustained earnings growth (Pages 5, 10).
Expectation of capital expenditure being self-reliant with minimal external funding, supporting controlled costs (Page 14).

See what Beta Drugs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Current CAPEX already incurred is around Rs.18-19 crores (Rs.7.5 crores building, Rs.11.5 crores machinery).
No major CAPEX planned except adding one line in API for new GMP.
Company has enough reserves for CAPEX; may borrow 1-2 crores from bank if needed but is largely self-reliant.
Cash and cash equivalents exceed outside borrowings by at least Rs.1 crore, indicating no immediate debt raising.
No mention of any current or near-term equity fundraising in the call.
Focus is on internal accruals and maintaining low-cost finance (CFO’s bandwidth includes getting lowest interest rate and maximizing cash reserves).
Overall, Beta Drugs does not currently plan major new fundraising through debt or equity beyond minor bank borrowing for CAPEX if required.

Order book

The transcript does not explicitly mention the current or expected orderbook or pending orders in exact figures.
Rahul Batra emphasizes a large and aggressive product development pipeline with 35 new molecules planned by 2025.
The company is focused on launching 8-12 molecules by 2023-24, indicating strong future order potential.
There is an ongoing effort to build international client relationships, especially in CIS countries and exports, suggesting growing order inflow over the next few years.
Capacity utilization shows levers: 60%-70% available for oral facility and 40%-50% for injectable (lyophilizers), indicating room to handle increased orders.
Overall, a clear roadmap is in place for 30% annual growth with expanding domestic and export markets, implying steady and growing order flow ahead.

See what Beta Drugs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

- Beta Drugs has incurred CAPEX of around Rs.18-19 crores recently (Rs.7.5 crores in building, Rs.11.5 crores in machinery). - Planned CAPEX mainly includes adding one new API line for new GMP compliance. - Additional CAPEX requirements are minimal; the company is largely self-reliant with enough reserves. - If needed, a small amount (1-2 crores) may be borrowed from banks. - Expansion plans include acquisition of land approved for manufacturing intermediates, multiple blocks, new formulation plant, and new API plant. - Work on the new land and expansion has already started. - Overall strategy includes steady CAPEX to support growth, targeting turnover of Rs.300-350 crores from current capacities. - Focus on backward integration and capacity enhancement, including increasing lyophilized injectable capacity by threefold. This summarizes current and near-term capital investment plans discussed.

Track Beta Drugs Ltd — get its next earnings analysis in your feed

Margin guidance

Category 2

Revenue growth guidance of 30% annually for the next 3-4 years (Page 6).
EBITDA margin expected to improve by 100 basis points in FY22-23 from 24% to 24.5%, targeting 26-27% margins in 3-4 years (Page 6).
Net profit increased by 112% in FY22 already, signaling strong earnings momentum (Page 2).
EBITDA margin expansion driven by higher sales of own brands, exports, and cost realizations (Page 2).
Further margin improvement expected from increased penetration in international markets which have higher price realization (Page 6).
Continued focus on new product launches, market penetration especially in domestic and regulated markets supports sustained earnings growth (Pages 5, 10).
Expectation of capital expenditure being self-reliant with minimal external funding, supporting controlled costs (Page 14).

Order book

The transcript does not explicitly mention the current or expected orderbook or pending orders in exact figures.
Rahul Batra emphasizes a large and aggressive product development pipeline with 35 new molecules planned by 2025.
The company is focused on launching 8-12 molecules by 2023-24, indicating strong future order potential.
There is an ongoing effort to build international client relationships, especially in CIS countries and exports, suggesting growing order inflow over the next few years.
Capacity utilization shows levers: 60%-70% available for oral facility and 40%-50% for injectable (lyophilizers), indicating room to handle increased orders.
Overall, a clear roadmap is in place for 30% annual growth with expanding domestic and export markets, implying steady and growing order flow ahead.

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisBeta Drugs Ltd

Rev 2Mar 2

See where Beta Drugs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Beta Drugs Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Beta Drugs Ltd Q4 FY22 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Margin guidance

Order book

How does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season